Application of cinnefungin to treatment of cancer
Through the combined use of sinaifenin and PARP inhibitors, TGS1 activity is inhibited, DNA repair mechanism is destroyed, and the problem of pancreatic cancer resistance to existing therapies is solved, which significantly improves the therapeutic effect and survival and reduces side effects.
Patent Information
- Application Number
- CN202411149105.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-21
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-08-21
AI Technical Summary
Pancreatic cancer shows resistance to existing radiotherapy and chemotherapy treatments, resulting in poor treatment effects and some patients have poor response to conventional therapies, especially those without BRCA mutations.
Sinaifenin alone or in combination with PARP inhibitors is used as a TGS1 inhibitor. By inhibiting the activity of TGS1, the DNA repair mechanism is destroyed, and the sensitivity of pancreatic cancer cells to genotoxicity is enhanced, thereby improving the therapeutic effect.
The combined use of sinaifenin and PARP inhibitors significantly enhanced the sensitivity of pancreatic cancer cells to chemotherapy drugs, prolonged patient survival, reduced side effects of treatment, and improved the effectiveness of treatment.
Smart Images

Figure CN119015299A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of biomedicine, and in particular to the application of sinefungin in treating cancer. Background Art
[0002] Pancreatic adenocarcinoma (PAAD) is a highly lethal and aggressive solid malignancy. Most patients are diagnosed with advanced stage and systemic metastasis, which are not suitable for surgical treatment. Standard treatment for pancreatic cancer includes radiotherapy and chemotherapy, which can also be used as adjuvant therapy after surgery, but pancreatic cancer usually shows resistance to these therapies, which seriously affects the treatment effect and patient prognosis. Therefore, overcoming drug resistance and adverse reactions of treatment regimens is crucial to enhance treatment response. Through genomic features determined by whole exome sequencing, pancreatic cancer tumors are divided into four subtypes: stable, locally rearranged, dispersed, and unstable. Unstable subtypes characterized by BRCA1 / 2, PALB2, RAD51C, RAD51D, and ATM account for 4% to 7%. Due to the synthetic lethal mechanism, these genetic changes make tumors particularly sensitive to PARP inhibitors. The results of the Phase III clinical trial of Pancreatic Olaparib (POLO) POLO trial showed that the progression-free survival of patients with BRCA-mutated pancreatic cancer treated with Olaparib was significantly longer than that of placebo. Currently, Olaparib maintenance treatment for patients with germline BRCA-mutated metastatic pancreatic cancer has been approved in many countries and is recommended in the National Comprehensive Cancer Network clinical guidelines. Although treatments such as Olaparib have been successful in clinical trials of BRCA-mutated pancreatic cancer, a large proportion of patients without these mutations still do not respond well to conventional therapies. Summary of the invention
[0003] In view of the defects of the prior art, the purpose of the present invention is to provide a new application of Sinaifungin. Specifically, it is a drug use of Sinaifungin alone or in combination with PARPi for the treatment of pancreatic cancer. After in vitro and in vivo experiments, it is proposed for the first time that Sinaifungin alone or in combination with PARPi can be used to treat pancreatic cancer. Breaking through the limitations of gene mutations in the treatment of pancreatic cancer, expanding the indications of PARPi in pancreatic cancer patients, enhancing the therapeutic effect of combined medication, prolonging the survival of pancreatic cancer patients, and enabling patients to benefit more from it.
[0004] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions.
[0005] The invention discloses the use of a TGS1 inhibitor as the only active ingredient in preparing a medicine for treating tumors.
[0006] The present invention also discloses the use of a TGS1 inhibitor as the sole active ingredient in the preparation of a drug for inhibiting the proliferation and invasion ability of tumor cells.
[0007] Furthermore, the above-mentioned use is characterized in that the TGS1 inhibitor includes sinefungin or shRNA; the shRNA nucleotide sequence is shown in SEQ ID No. 1~3.
[0008] The present invention also discloses a pharmaceutical composition, characterized in that the pharmaceutical composition comprises a TGS1 inhibitor and a PARP inhibitor.
[0009] The present invention also discloses a pharmaceutical composition, characterized in that the pharmaceutical composition comprises a TGS1 inhibitor and a chemotherapeutic drug.
[0010] Furthermore, the pharmaceutical composition described above is characterized in that the TGS1 inhibitor comprises sinefungin or shRNA; the shRNA nucleotide sequence is as shown in SEQ ID No. 1-3.
[0011] The present invention also discloses a pharmaceutical preparation, characterized in that the pharmaceutical preparation comprises a TGS1 inhibitor or a combination of a TGS1 inhibitor and a PARP inhibitor or a combination of a TGS1 inhibitor and a chemotherapeutic drug.
[0012] The present invention also discloses a radio / chemotherapy sensitizer, characterized in that it comprises a TGS1 inhibitor.
[0013] Furthermore, the above-mentioned pharmaceutical preparation or the above-mentioned radio / chemosensitizer is characterized in that the TGS1 inhibitor includes sinefungin or shRNA; the shRNA nucleotide sequence is shown in SEQ ID No. 1~3.
[0014] The present invention also discloses the use of the above-mentioned pharmaceutical composition, the above-mentioned pharmaceutical preparation or the above-mentioned radio / chemotherapy sensitizer in the preparation of drugs for treating tumors.
[0015] Trimethylguanosine synthase 1 (TGS1) is a conserved hypermethylating enzyme involved in the capping of mRNA and small nuclear RNA (snRNA) and is involved in key biological processes, including glucose metabolism and embryonic development. In this study, our results indicate that TGS1 is a key player in DNA repair. Studies have shown that TGS1 is significantly overexpressed in pancreatic cancer and is associated with poor prognosis and increased chemoresistance. Mechanistically, TGS1 is essential for recruiting BRCA1 to sites of DNA damage to promote HR repair. Inhibition of TGS1 by genetic knockdown or pharmacological intervention with sinefungin (sinefungin) impairs HR repair and enhances the sensitivity of pancreatic cancer cells to genotoxic treatments. This study highlights the therapeutic potential of TGS1 inhibition as part of a combination strategy with existing therapeutic approaches such as PARP inhibitors to improve outcomes in patients with pancreatic cancer.
[0016] In pancreatic cancer, elevated expression of TGS1 is associated with defective homologous recombination repair. However, when TGS1 is inhibited, it leads to decreased BRCA1 levels, resulting in defective homologous recombination repair and significantly increasing the sensitivity of pancreatic cancer cells to PARPi.
[0017] Compared with the prior art, the beneficial effects of the present invention are as follows.
[0018] 1. The effective dose of combined use of sinefungin is small, metabolism is rapid, and toxic side effects are likely to be small.
[0019] 2. Sinafenac targets TGS1, has a narrow spectrum of action and a low off-target rate, and is less likely to cause other toxic side effects.
[0020] 3. Sinafenac can significantly enhance the killing ability of PARPi. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1Transfection of PAAD cell lines with TGS1 shRNA affects the sensitivity of cells to radiotherapy and chemotherapy. (A) Western blot shows the expression of TGS1 in PAAD cell lines PANC-1, Mia-2, CFPAC-1, ASPC-1, BXPC-3 and SW1990; (B) Western blot shows the protein level of TGS1 in PANC-1 cells transfected with TGS1 shRNA; (C) Western blot shows the protein level of TGS1 in Mia-2 cells transfected with TGS1 shRNA. (D) Western blot showing the protein level of TGS1 in CFPAC-1 cells transfected with TGS1 shRNA; (EH) The results of clone formation assays showing the cell survival rate of Mia-2 cells transfected with TGS1 shRNA after irradiation (E), olaparib (F), cisplatin (G), and etoposide (H); (IL) The results of clone formation assays showing the cell survival rate of CFPAC-1 cells transfected with TGS1 shRNA after irradiation (I), olaparib (J), cisplatin (K), and etoposide (L). Data points with error bars represent mean ± standard deviation. Statistical analysis was performed using unpaired two-tailed ANOVA. *P<0.05; **P<0.01.
[0022] Figure 2 The sensitivity of PANC-1 cells to olaparib was tested after transfection of TGS1 shRNA plasmid. (AD) The results of the clonogenic assay showed the cell survival rate after exposure to irradiation (A), olaparib (B), cisplatin (C), and etoposide (D) in PANC-1 cells transfected with TGS1 shRNA; (EH) Flow chart of the sensitivity of the PANC-1 cell-derived xenograft model (CDX) transfected with TGS1 shRNA to olaparib (n=5 mice per group). Tumor growth curves (F), representative images of tumors (G), and tumor weights (H) of CDX model mice treated with PBS, olaparib, TGS1shRNA, and olaparib+TGS1shRNA; (I) Western blot detection of protein levels of cleaved caspase3, γ-H2AX, pCHK2, and cleaved PARP in tumor tissues of CDX model mice treated with shTGS1 and olaparib; (J) Immunohistochemical analysis showed H&E staining, Ki-67, γ-H2AX, and cleaved caspase3 expression after olaparib treatment and knockdown of TGS1; (K) Immunohistochemical statistics showed the proportion of Ki-67, γ-H2AX, and cleaved caspase3-positive cells after olaparib treatment and knockdown of TGS1. Scale bar, 50 μm. Data points with error bars represent mean ± standard deviation. Unpaired t-test and unpaired two-tailed ANOVA statistical analysis were performed. *P<0.05; **P<0.01.
[0023] Figure 3 Sinefungin induces the sensitivity of pancreatic cancer cell lines Mia-2 and CFPAC-1 to olaparib by inhibiting TGS1. (AC) Western immunoblot results show the protein level of TGS1 in PANC-1 (A), Mia-2 (B), and CFPAC-1 (C) cells treated with sinefungin (10 μM, 20 μM); (DG) Clonogenic assay results show the cell survival rate of sinefungin-treated Mia-2 cells exposed to radiation (D), olaparib (E), cisplatin (F), or etoposide (G); (HK) Clonogenic assay results show the cell survival rate of sinefungin-treated CFPAC-1 cells exposed to radiation (H), olaparib (I), cisplatin (J), or etoposide (K). Data points with error bars represent the mean with standard deviation. Statistical analysis was performed using unpaired two-tailed ANOVA. *p<0.05; **p<0.01. NS represents no difference.
[0024] Figure 4 Figure 2 shows the sensitivity of pancreatic cancer cell line PANC-1 to olaparib induced by sinefungin through inhibition of TGS1. (AD) The effect of sinefungin on the survival rate of PANC-1 cells exposed to irradiation (A), olaparib (B), cisplatin (C) and etoposide (D) in the clonogenic assay; (E) Flow chart of PANC-1 cell-derived xenograft model (CDX); (FH) Representative images of tumors (F), tumor growth curves (G) and tumor weights (H) in CDX models treated with PBS, olaparib, sinefungin or olaparib + sinefungin combination; (I) Immunohistochemical detection of caspase3, γ-H2AX, pCHK2 and PARP expression in CDX models; (KN) Immunohistochemical detection of Ki-67, γ-H2AX and Cleaved caspase3 expression in CDX models. Data points with error bars represent the mean with standard deviation. Statistical analysis was performed using unpaired t-test and unpaired two-tailed ANOVA. *p<0.05; **p<0.01.
[0025] Figure 5Figure 1. Sinefungin inhibits TGS1-induced olaparib sensitivity of pancreatic cancer patient-derived xenograft PDX 1301. (A) Flow chart of olaparib and sinefungin treatment of PDX models; (BD) Differences in serum AST (B), serum ALT (C), and mouse body weight (D) between PBS, olaparib, sinefungin, and olaparib + sinefungin in the PDX 1301 model; (EG) Representative images (E), tumor growth curves (F), and tumor weights (G) of PDX 1301 tumors treated with PBS, olaparib, or sinefungin; (HK) Representative images and quantification of HE staining, ki-67, γ-H2AX, and caspase3 in PDX 1301 treated with PBS, olaparib, or sinefungin; (L) Protein expression of cleaved caspase3, γ-H2AX, pCHK2, and PARP in tumors of the PDX 1301 model. Data points with error bars represent mean values with standard deviations. Statistical analysis was performed using unpaired t-test and unpaired two-tailed ANOVA. *p<0.05; **p<0.01. NS means no difference.
[0026] Figure 6 Figure 1 shows the olaparib sensitivity of pancreatic cancer patient-derived xenograft PDX 748 induced by sinefungin inhibition of TGS1. (AC) Differences in serum AST (A), serum ALT (B), and mouse body weight (C) between PBS, olaparib, sinefungin, and olaparib + sinefungin in the PDX 748 model; (DF) Representative images (D), tumor growth curves (E), and tumor weights (F) of PDX748 tumors treated with PBS, olaparib, or sinefungin; (GJ) Representative images and quantification of HE staining, ki-67, γ-H2AX, and caspase3 in PDX 748 treated with PBS, olaparib, or sinefungin; (K) Protein expression of cleaved caspase3, γ-H2AX, pCHK2, and PARP in tumors in the PDX748 model. Data points with error bars represent the mean with standard deviation. Statistical analysis was performed using unpaired t-test and unpaired two-tailed ANOVA. *p<0.05; **p<0.01. NS means no difference. DETAILED DESCRIPTION
[0027] The present invention is further described in detail below with specific embodiments, but it should not be understood that the scope of the above subject matter of the present invention is limited to the following embodiments, and all technologies realized based on the content of the present invention belong to the scope of the present invention.
[0028] Unless otherwise specified, all reagents and materials used in the present invention are commercially available.
[0029] Embodiment 1.
[0030] 1. Materials and methods.
[0031] 1. Cell culture.
[0032] PAAD cell lines were purchased from the Cell Resource Center of Peking Union Medical College (affiliated to the National Science and Technology Infrastructure, National Biomedical Cell Line Resource, NSTI-BMCR. http: / / cellresource.cn). ASPC-1 cells, BXPC-3 cells, and PANC-1 cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% (v / v) fetal bovine serum and 1% penicillin-streptomycin. Mia-2 cells were cultured in DMEM containing 5% (v / v) horse serum. CFPAC-1 cells were maintained in IMDM medium containing 10% (v / v) FBS.
[0033] 2. Western Blotting and Antibodies.
[0034] Cells were harvested and lysed with NETN buffer (20 mM Tris-HCl pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5% Nonidet P-40 with 10 mM NaF trypsin inhibitor and 20 mM β-glycerophosphate × saline). The immunoprecipitate was washed with NETN and then centrifuged at 500 × g for 1 min for a total of 3 times. 50 μL of the immunoprecipitate was set aside and 50 μL of 1× Laemmli buffer was added, followed by boiling at 95°C for 10 min. Protein samples were separated by SDS-PAGE and transferred to PVDF membranes (Millipore, Germany). After blocking with 5% skim milk and 0.1% Tween-20 (A100777, Sangon Biotech, Shanghai, China) in TBST (Solerbo, China), the membrane was incubated with TGS1 antibody (1:1000, Bethyl, A304-922A, USA) or GAPDH (1:10000, Proteintech, 10494-1-AP, USA) at 4°C overnight, followed by incubation with secondary antibody (Jackson, USA) for 1 hour. The membrane was then washed three times with TBST, and protein bands were detected on an Amersham ImageQuant 800 (Cytiva, US) machine using Super ECL plus (NCM, P10300, China). Tumor tissues were collected and total protein was extracted for each group. The protein cleavage products were incubated with cleaved PARP (1:1000, 5625S, CST, USA), cleaved caspase3 (1:1000, 9661S, CST, USA), γ-H2AX (1:1000, 05-636, Millipore, USA) and pCHK2 (1:1000, 82263S, Proteintech, USA) overnight as indicated by western blotting.
[0035] 3. Cell activity assay.
[0036] Cells were seeded in 6-well plates at a concentration of 500-1000 cells per well. The next day, PANC-1 / Mia-2 / CFPAC-1 cells were treated with different doses of sinefungin (0, 10, 20 μM), olaparib (0, 0.5, 1, 2 μM), or X-rays (1 / 2 / 4 / 8 Gy). Culture was continued for 10-14 days, and then the colonies were stained with 0.1% crystal violet solution. The number of colonies in each well was quantified, and the survival ratio was calculated by comparing the number of colonies in treated and untreated wells. Viable cells were measured using a cell counting kit-8 (CCK-8, PSAITONG). Cells were seeded into 96-well plates. The next day, PANC-1 / Mia-2 / CFPAC-1 cells were treated with different doses of cisplatin (0, 6.25, 12.5, 25 μM) and etoposide (0, 3.125, 6.25, 12.5, 25 μM). Next, the cells were exposed to 8 μL of CCK-8 reagent (100 μL of culture medium per well) for 1 hour in an incubator at 37°C and 5% CO2. The absorbance at a wavelength of 450 nm was measured using a BioTek microplate reader (800TS).
[0037] 4. Validation of pancreatic cancer cell-derived and patient-derived xenograft models.
[0038] The cell-derived xenograft (CDX) model was established using 5- to 6-week-old female thymic nude mice (BALB / c-nu). 6 A suspension of pancreatic cancer cells (including PANC-1 and PANC-1 cell lines transfected with TGS1 shRNA) was mixed with 50% Matrigel and injected subcutaneously into the anterior region of each mouse. About 20 days after inoculation, the mice were divided into different treatment groups, including a TGS1 inhibition group (sinefungin, 20 mg / kg, intraperitoneal injection, once every other day), an olaparib group (20 mg / kg, intraperitoneal injection, once every other day for two weeks), and a TGS1 inhibitor and olaparib combination treatment group. The different groupings are shown in the attached figure.
[0039] Pancreatic cancer patient-derived xenograft (PDX) models were obtained from Nanjing Changle Biotechnology Co., Ltd. Models with high TGS1 expression (PDX-1301 and 748) were selected for explantation. Biopsies of PDX tumors were subcutaneously implanted into BALB / c-nu female mice. Once the average tumor volume of the PDX model reached 100 mm 3 , mice were randomly assigned to treatment cohorts, including PBS alone, TGS1 inhibition (sinefungin, 20 mg / kg, i.p., every other day), olaparib (20 mg / kg, i.p., every other day), and the combination of sinefungin and olaparib.
[0040] In all mouse studies, the length and width of each tumor were measured every other day using electronic calipers. Tumor volume was calculated using the formula: Volume = 0.5 (length × width) 2 At the end of the experiment (the end point of the experiment was that the tumor diameter did not exceed 1.5 cm), the animals were euthanized, and part of the tumor tissue was quickly fixed in 4% paraformaldehyde for immunohistochemistry (IHC) analysis, and the rest of the tumor tissue was stored at -80°C. Tumor tissues of CDX and PDX were collected for immunohistochemistry staining. Fresh tumor tissues were fixed with 4% paraformaldehyde fixative overnight, dehydrated and embedded in paraffin. Samples were subjected to immunohistochemistry staining. Tissues were stained with H&E, Ki-67 (1:1000, 28074-1-AP, Proteintech, USA), cleaved caspase3 (1:1000, 9661S, CST, USA), and γ-H2AX (1:1000, 05-636, Millipore, USA) antibodies. Images of 10 random microscopic stained areas in each section were recorded using ImageJ software for quantitative analysis.
[0041] 2. Experimental results.
[0042] 1. TGS1 shRNA inhibits TGS1-induced sensitivity of pancreatic cancer cell lines to olaparib.
[0043] The experimental results are as follows Figure 1 , as shown in Figure 2. Using clone formation assay and cell proliferation assay, it was proved that TGS1 shRNA combined with radiotherapy, olaparib, cisplatin and etoposide could significantly inhibit the cell survival rate of PANC-1 cells, Mia-2 cells and CFPAC-1 cells. PANC-1 cells and PANC-1 cell-derived xenograft models (CDX) transfected with TGS1 shRNA were treated with PBS and olaparib. According to the representative pictures, growth curves and tumor weight results, the TGS1 shRNA group combined with olaparib treatment was the best. Immunohistochemistry was used to verify that the expression of caspase3, γ-H2AX, pCHK2 and PARP in the TGS1 shRNA group combined with olaparib treatment group increased; Ki-67 expression decreased; γ-H2AX and cleavedcaspase3 expression increased.
[0044] 2. Sinefungin inhibits TGS1 to induce sensitivity of pancreatic cancer cell lines to olaparib.
[0045] The experimental results are as follows Figure 3, as shown in Figure 4. Using clone formation assay and cell proliferation assay, it was proved that different doses of sinefungin combined with radiotherapy, olaparib, cisplatin and etoposide could significantly inhibit the survival rate of PANC-1 cells. PANC-1 cell-derived xenograft model (CDX) was treated with PBS, olaparib, sinefungin or olaparib and sinefungin. According to the representative pictures, growth curves and tumor weight results, the combination of olaparib and sinefungin was the best. Immunohistochemistry was used to verify that the expression of caspase3, γ-H2AX, pCHK2 and PARP in the combination treatment group of olaparib and sinefungin increased; the expression of Ki-67 decreased; and the expression of γ-H2AX and cleavedcaspase3 increased.
[0046] 3. Sinefungin inhibits TGS1 to induce sensitivity of pancreatic cancer patient tissue-derived xenograft models (PDX) to olaparib.
[0047] The experimental results are as follows Figure 5 , 6. Pancreatic cancer patient tissue-derived xenograft models (PDX) were treated with PBS, olaparib, sinefungin, or olaparib and sinefungin combined. Based on representative images, growth curves, and tumor weight results, olaparib and sinefungin combined treatment was optimal. Immunohistochemistry was used to verify that the expression of caspase3, γ-H2AX, pCHK2, and PARP increased in the olaparib and sinefungin combined treatment group; the expression of Ki-67 decreased; and the expression of γ-H2AX and cleaved caspase3 increased.
[0048] In summary, the combination of sinefungin and PARP inhibitors significantly inhibited tumor growth in cell-derived xenograft (CDX) and patient-derived xenograft (PDX) models with high TGS1 expression. This invention not only highlights the potential of sinefungin as a therapeutic drug to improve the effectiveness of existing pancreatic cancer treatments, but also provides a new way to address major clinical challenges associated with pancreatic cancer.
[0049] The above description is only a preferred embodiment of the present invention and is not intended to limit the scope of the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. The use of TGS1 inhibitors as the sole active ingredient in the preparation of drugs for treating tumors.
2. The use of TGS1 inhibitors as the sole active ingredient in the preparation of drugs that inhibit the proliferation and invasion ability of tumor cells.
3. The use according to claim 1 or 2, characterized in that: The TGS1 inhibitor includes sinefungin or shRNA; the shRNA nucleotide sequence is shown in SEQ ID No. 1-3.
4. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises a TGS1 inhibitor and a PARP inhibitor.
5. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises a TGS1 inhibitor and a chemotherapeutic drug.
6. The pharmaceutical composition according to claim 4 or 5, characterized in that The TGS1 inhibitor includes sinefungin or shRNA; the shRNA nucleotide sequence is shown in SEQ ID No. 1-3.
7. A pharmaceutical preparation, characterized in that The pharmaceutical preparation comprises a TGS1 inhibitor or a combination of a TGS1 inhibitor and a PARP inhibitor or a combination of a TGS1 inhibitor and a chemotherapeutic drug.
8. A radio / chemotherapy sensitizer, characterized in that: Contains a TGS1 inhibitor.
9. The pharmaceutical preparation according to claim 7 or the radio / chemotherapy sensitizer according to claim 8, characterized in that: The TGS1 inhibitor includes sinefungin or shRNA; the shRNA nucleotide sequence is shown in SEQ ID No. 1-3.
10. Use of the pharmaceutical composition according to claims 4-5, the pharmaceutical preparation according to claim 7, or the radio / chemotherapy sensitizer according to claim 8 in the preparation of a drug for treating tumors.
Citation Information
Patent Citations
Sinefungin analog and preparation method thereof
CN108484705A
Combination use of substituted 4-aminoisoindoline-1, 3-dione compound and second active agent
CN114786665A
Antiproliferative compounds and second active agents for treatment of multiple myeloma
CN118178417A
Sinefungin derivatives, their preparation and their application in therapeutics
FR2664277A1
Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and a PARP inhibitor
US20210023077A1
